Clinicopathological features of medulloblastoma: An overview with an emphasis on molecular biology

Clinical Neuropathology

Volumn 26, Issue 3, 2007, Pages 93-110

  De Haas, T G K J ^a   Kool, M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cerebellum; Embryonal brain tumor; Medulloblastoma

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPAMINE; CYCLOPHOSPHAMIDE; CYTARABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; IFOSFAMIDE; LOMUSTINE; MANNITOL; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; NOTCH2 RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PREDNISONE; PROCARBAZINE; PROTEIN MDM2; S6 KINASE; SCATTER FACTOR RECEPTOR; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR OTX2; VINCRISTINE;

ALTERNATIVE MEDICINE; BRAIN DEVELOPMENT; CANCER GENETICS; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CARCINOGENESIS; CEREBELLUM; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID CYTOLOGY; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME ABERRATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE GENOMIC HYBRIDIZATION; DANDY WALKER SYNDROME; DRUG MEGADOSE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE MUTATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; KNOCKOUT MOUSE; MEDULLOBLASTOMA; MICROARRAY ANALYSIS; MONOTHERAPY; MYCN GENE; NERVE CELL DIFFERENTIATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; ONCOGENE MYC; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SERIAL ANALYSIS OF GENE EXPRESSION; SYMPTOMATOLOGY; TUMOR BIOPSY;

EID: 34249276339     PISSN: 07225091     EISSN: None     Source Type: Journal    
DOI: 10.5414/npp26093     Document Type: Review

References (124)

1. Aldosari N, Bigner SH, Burger PC, Becker L, Kepner JL, Friedman HS, McLendon RE. MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med. 2002; 126: 540-544.
2. Allen ED, Byrd SE, Darling CF, Tomita T, Wilczynski MA. The clinical and radiological evaluation of primary brain tumors in children, Part I: Clinical evaluation. J Natl Med Assoc. 1993; 85: 445-451.
3. Arseni C, Constantinescu A, Danaila L. 1976. Supratentorial dissemination of medulloblastomas. Schweiz Arch Neurol Neurochir Psychiatr. 1976; 119: 299-306.
4. Avet-Loiseau H, Venuat AM, Terrier-Lacombe MJ, Lellouch-Tubiana A, Zerah M, Vassal G. Comparative genomic hybridization detects many recurrent imbalances in central nervous system primitive neuroectodermal tumours in children. Br J Cancer. 1999; 79: 1843-1847.
5. Badiali M, Pession A, Basso G, Andreini L, Rigobello L, Galassi E, Giangaspero F. N-myc and c-myc oncogenes amplification in medulloblastomas. Evidence of particularly aggressive behavior of a tumor with c-myc amplification. Tumori. 1991; 77: 118-121.
6. Bailey P, Cushing H. Medulloblastoma cerebelli: a common type of midcerebellar glioma of childhood. Arch Neurol Psychiatry. 1925; 14: 192-223.
7. Bayani J, Zielenska M, Marrano P, Kwan Ng Y, Taylor MD, Jay V, Rutka JT, Squire JA. Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. J Neurosurg. 2000; 93: 437-448.
8. Berman DM, Karhadkar SS, Hallahan AR, Pritchard JI, Eberhart CG, Watkins DN, Chen JK, Cooper MK, Taipale J, Olson JM, Beachy PA. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science. 2002; 297: 1559-1561.
9. Boon K, Eberhart C, Riggins G. Genomic amplification of Orthodenticle homolog 2 (OTX2) in medulloblastomas. Cancer Res. 2005; 65: 703-707.
10. Boon K, Edwards J, Siu I, Olschner D, Eberhart C, Marra M, Strausberg R, Riggins G. Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene. 2003; 22: 7687-7694.
11. Browd SR, Kenney AM, Gottfried ON, Yoon JW, Walterhouse D, Pedone CA, Fults DW. N-myc can substitute for insulin-like growth factor signaling in a mouse model of sonic hedgehog-induced medulloblastoma. Cancer Res. 2006; 66: 2666-2672.
12. Buhring U, Strayle-Batra M, Freudenstein D, Scheel-Walter HG, Kuker W. MRI features of primary, secondary and metastatic medulloblastoma. Eur Radiol. 2002; 12: 1342-1348.
13. Clerico A, Sordi A, Ragni G, Festa A, Cappelli C, Maini CL. Brief report: transient mutism following posterior fossa surgery studied by single photon emission computed tomography (SPECT). Med Pediatr Oncol. 2002; 38: 445-448.
14. Cogen PH, Daneshvar L, Metzger AK, Edwards MS. Deletion mapping of the medulloblastoma locus on chromosome 17p. Genomics. 1990; 8: 279-285.
15. Cohen MM Jr. The hedgehog signaling network. Am J Med Genet A. 2003; 123: 5-28.
16. Cooper MK, Porter JA, Young KE, Beachy PA. Teratogen-mediated inhibition of target tissue response to Shh signaling. Science. 1998; 280: 1603-1607.
17. Dahmane N, Ruiz I Altaba A. Sonic hedgehog regulates the growth and patterning of the cerebellum. Development. 1999; 126: 3089-3100.
18. de Haas T, Oussoren E, Grajkowska W, Perek-Polnik M, Popovic M, Zadravec- Zaletel L, Perera M, Corte G, Wirths O, van Sluis P, Pietsch T, Troost D, Baas F, Versteeg R, Kool M. OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas. J Neuropathol Exp Neurol. 2006; 65: 176-186.
19. Deutsch M, Laurent JP, Cohen ME. Myelography for staging medulloblastoma. Cancer. 1985; 56: 1763-1766.
20. Di C, Liao S, Adamson DC, Parrett TJ, Broderick DK, Shi Q, Lengauer C, Cummins JM, Velculescu VE, Fults D, McLendon RE, Bigner DD, Yan H. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans-retinoic acid. Cancer Res. 2005; 65: 719-724.
21. Dietze DD Jr, Mickle JP. Cerebellar mutism after posterior fossa surgery. Pediatr Neurosurg. 1990; 16: 25-31.
22. Dyer MA. Mouse models of childhood cancer of the nervous system. J Clin Pathol. 2004; 57: 561-576.
23. Eberhart CG. Medulloblastoma in mice lacking p53 and PARP: all roads lead to Gli. Am J Pathol. 2003; 162: 7-10.
24. Eberhart CG, Kepner JL, Goldthwaite PT, Kun LE, Duffner PK, Friedman HS, Strother DR, Burger PC. Histopathologic grading of medulloblastomas. Cancer. 2002; 94: 552-560.
25. Eberhart CG, Kratz J, Wang Y, Summers K, Stearns D, Cohen K, Dang CV, Burger PC. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol. 2004; 63: 441-449.
26. Eberhart CG, Kratz JE, Schuster A, Goldthwaite P, Cohen KJ, Perlman EJ, Burger PC. Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol. 2002; 12: 36-44.
27. Ehrbrecht A, Muller U, Wolter M, Hoischen A, Koch A, Radlwimmer B, Actor B, Mincheva A, Pietsch T, Lichter P, Reifenberger G, Weber RG. Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components. J Pathol. 2006; 208: 554-563.
28. Ellison DW, Onilude OE, Lindsey JC, Lusher ME, Weston CL, Taylor RE, Pearson AD, Clifford SC. β-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol. 2005; 23: 7951-7957.
29. Ersahin Y, Yararbas U, Duman Y, Mutluer S. Single photon emission tomography following posterior fossa surgery in patients with and without mutism. Childs Nerv Syst. 2002; 18: 318-325.
30. Fan X, Mikolaenko I, Elhassan I, Ni X, Wang Y, Ball D, Brat DJ, Perry A, Eberhart CG. Notch 1 and notch 2 have opposite effects on embryonal brain tumor growth. Cancer Res. 2004; 64: 7787-7793.
31. Fan X, Wang Y, Kratz J, Brat DJ, Robitaille Y, Moghrabi A, Perlman EJ, Dang CV, Burger PC, Eberhart CG. hTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors. Am J Pathol. 2003; 162: 1763-1769.
32. Freeman CR, Taylor RE, Kortmann RD, Carrie C. Radiotherapy for medulloblastoma in children: a perspective on current international clinical research efforts. Med Pediatr Oncol. 2002; 39: 99-108.
33. Fujii Y, Hongo T, Hayashi Y. Chromosome analysis of brain tumors in childhood. Genes Chromosomes Cancer. 1994; 11: 205-215.
34. Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahem V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Lau C, Boyett JM, Wallace D, Gilbertson RJ. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006; 7: 813-820.
35. Gajjar A, Hernan R, Kocak M, Fuller C, Lee Y, McKinnon PJ, Wallace D, Lau C, Chintagumpala M, Ashley DM, Kellie SJ, Kun L, Gilbertson RJ. Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma. J Clin Oncol. 2004; 22: 984-993. Epub 2004 Feb 2017.
36. Gatta G, Capocaccia R, Coleman MP, Gloeckler Ries LA, Berrino F. Childhood cancer survival in Europe and the United States. Cancer. 2002; 95: 1767-1772.
37. Giangaspero F, Rigobello L, Badiali M, Loda M, Andreini L, Basso G, Zorzi F, Montaldi A. Large-cell medulloblastomas. A distinct variant with highly aggressive behavior. Am J Surg Pathol. 1992; 16: 687-693.
38. Giangaspero F, Perilongo G, Fondelli MP, Brisigotti M, Carollo C, Burnelli R, Burger PC, Garre ML. Medulloblastoma with extensive nodularity: a variant with favorable prognosis. J Neurosurg. 1999; 91: 971-977.
39. Gilbertson R, Wickramasinghe C, Hernan R, Balaji V, Hunt D, Jones-Wallace D, Crolla J, Perry R, Lunec J, Pearson A, Ellison D. Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer. 2001; 85: 705-712.
40. Gilbertson RJ, Clifford SC. PDGFRB is overexpressed in metastatic medulloblastoma. Nat Genet. 2003; 35: 197-198.
41. Gilhuis HJ, Anderl KL, Boerman RH, Jeuken JM, James CD, Raffel C, Scheithauer BW, Jenkins RB. Comparative genomic hybridization of medulloblastomas and clinical relevance: eleven new cases and a review of the literature. Clin Neurol Neurosurg. 2000; 102: 203-209.
42. Gilthorpe JD, Papantoniou EK, Chedotal A, Lumsden A, Wingate RJ. The migration of cerebellar rhombic lip derivatives. Development. 2002; 129: 4719-4728.
43. Giordana MT, Migheli A, Pavanelli E. Isochromosome 17q is a constant finding in medulloblastoma. An interphase cytogenetic study on tissue sections. Neuropathol Appi Neurobiol. 1998; 24: 233-238.
44. Goodrich LV, Milenkovic L, Higgins KM, Scott MP. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science. 1997; 277: 1109-1113.
45. Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem. 2006; 281: 22429-22433. Epub 2006 Jun 22.
46. Grotzer MA, Janss AJ, Phillips PC, Trojanowski JQ. Neurotrophin receptor TrkC predicts good clinical outcome in medulloblastoma and other primitive neuroectodermal brain rumors. Klin Padiatr. 2000; 212: 196-199.
47. Haberler C, Slavc I, Czech T, Gelpi E, Heinzl H, Budka H, Urban C, Scarpatetti M, Ebetsberger-Dachs G, Schindler C, Jones N, Klein-Franke A, Maier H, Jauk B, Kiefer A, Hainfellner JA. Histopathological prognostic factors in medulloblastoma: high expression of survivin is related to unfavourable outcome. Eur J Cancer. 2006; 42: 2996-3003. Epub 2006 Sep 2925.
48. Hamada H, Kurimoto M, Endo S, Ogiichi T, Akai T, Takaku A. Turcot's syndrome presenting with medulloblastoma and familiar adenomatous polyposis: a case report and review of the literature. Acta Neurochir (Wien). 1998; 140: 631-632.
49. Hamilton SR, Lui B, Parsons RE, Papadopoulos N, Jen J, Powell SM, Krush AJ, Berk T, Cohen Z, Tetu B et al. The molecular basis of Turcot's syndrome. N Engl J Med. 1995; 332: 839-847.
50. Hatton BA, Knoepfler PS, Kenney AM, Rowitch DH, de Alboran IM, Olson JM, Eisenman RN. N-myc is an essential downstream effector of shh signaling during both normal and neoplastic cerebellar growth. Cancer Res. 2006; 66: 8655-8661.
51. Heikens J, Michiels EM, Behrendt H, Endert E, Bakker PJ, Fliers E. Long-term neuro-endocrine sequelae after treatment for childhood medulloblastoma. Eur J Cancer. 1998; 34: 1592-1597.
52. Heinz R, Wiener D, Friedman H, Tien R. Detection of cerebrospinal fluid metastasis: CT myelography or MR? Am J Neuroradiol. 1995; 16: 1147-1151.
53. Herms J, Neidt I, Luscher B, Sommer A, Schurmann P Schroder T, Bergmann M, Wilken B, Probst-Cousin S, Hernaiz-Driever P, Behnke J, Hanefeld F, Pietsch T, Kretzschmar HA. C-myc expression in medulloblastoma and its prognostic value. Int J Cancer. 2000; 89: 395-402.
54. Hernan R, Fasheh R, Calabrese C, Frank AJ, Maclean KH, Allard D, Barraclough R, Gilbertson RJ. ERBB2 upregulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res. 2003; 63: 140-148.
55. Hui AB, Takano H, Lo KW, Kuo WL, Lam CN, Tong CY, Chang Q, Gray JW, Ng HK. Identification of a novel homozygous deletion region at 6q23.1 in medulloblastomas using high-resolution array comparative genomic hybridization analysis. Clin Cancer Res. 2005; 11: 4707-4716.
56. Inda MM, Mercapide J, Munoz J, Coullin P, Danglot G Tunon T, Martinez-Penuela JM, Rivera JM, Burgos JJ, Bernheim A, Castresana JS. PTEN and DMBTl homozygous deletion and expression in medulloblastomas and supratentorial primitive neuroectodermal tumors. Oncol Rep.2004; 12: 1341-1347.
57. Kalifa C, Grill J. The therapy of infantile malignant brain tumors: current status? J Neurooncol. 2005; 75: 279-285.
58. Kasper M, Regi G, Frischauf AM, Aberger F. GLI transcription factors: mediators of oncogenic Hedgehog signalling. Eur J Cancer. 2006; 42: 437-445. Epub 2006 Jan 2010.
59. Katsetos C, Del Valle L, Legido A, de Chadarevian J, Perentes E, Mork S. On the neuronal/neuroblastic nature of medulloblastomas; a tribute to Pio de Rio Hortega an Moises Polak. Acta Neuropathol. 2003; 105: 1-13.
60. Katsetos C, Herman M, Frankfurter A, Gass P, Collins V, Walker C, Rosemberg S, Barnard R, Rubinstein L. Cerebellar desmoplastic medulloblastomas. A further immunohistochemical characterization of the reticulin-free pale islands. Arch Pathol Lab Med. 1989; 113: 1019-1029.
61. Keeler RF. Cyclopamine and related steroidal alkaloid teratogens: their occurrence, structural relationship, and biologic effects. Lipids. 1978; 13: 708-715.
62. Kenney AM, Cole MD, Rowitch DH. Nmyc upregulation by sonic hedgehog signaling promotes proliferation in developing cerebellar granule neuron precursors. Development. 2003; 130: 15-28.
63. Kenney AM, Widlund HR, Rowitch DH. Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors. Development. 2004; 131: 217-228. Epub 2003 Dec 2003.
64. Kleihues P, Louis D, Scheithauer B, Rorke L, Reifenberger G, Burger P, Cavenee W. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol. 2002; 61: 215-225.
65. Knoepfler PS, Kenney AM. Neural precursor cycling at sonic speed: n-myc pedals, gsk-3 brakes. Cell Cycle. 2006; 5: 47-52. Epub 2006 Jan 2001.
66. Kopelson G, Linggood R, Kleinman GM. Medulloblastoma. The identification of prognostic subgroups and implications for multimodality management. Cancer. 1983; 51: 312-319.
67. Korshunov A, Golanov A, Ozerov S, Sycheva R. Prognostic value of tumor-associated antigens immunoreactivity and apoptosis in medulloblastomas. An analysis of 73 cases. Brain Tumor Pathol. 1999; 16: 37-44.
68. Kumar V, Phipps K, Harkness W, Hayward RD. Ventriculo-peritoneal shunt requirement in children with posterior fossa tumours: an 11-year audit. Br J Neurosurg. 1996; 10: 467-470.
69. Lee Y, McKinnon PJ. DNA ligase IV suppresses medulloblastoma formation. Cancer Res. 2002; 62: 6395-6399.
70. Lewis PM, Gritli-Linde A, Smeyne R, Kottmann A, Mc-Mahon AP. Sonic hedgehog signaling is required for expansion of granule neuron precursors and patterning of the mouse cerebellum. Dev Biol. 2004; 270: 393-410.
71. MacDonald TJ, Brown KM, LaFleur B, Peterson K, Lawlor C, Chen Y, Packer RJ, Cogen P, Stephan DA. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet. 2001 ; 29: 143-152.
72. Marino S, Vooijs M, van Der Gulden H, Jankers J, Berns A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. 2000; 14: 994-1004.
73. Matsutani M. Chemoradiotherapy for brain tumors: current status and perspectives. Int J Clin Oncol. 2004; 9: 471-474.
74. McCabe MG, Ichimura K, Liu L, Plant K, Backlund LM, Pearson DM, Collins VP. High-resolution array-based comparative genomic hybridization of medulloblastomas and supratentorial primitive neuroectodermal tumors. J Neuropathol Exp Neurol. 2006; 65: 549-561.
75. McNeil DE, Cote RT, Clegg L, Rorke LB. Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: A SEER update. Med Pediatr Oncol. 2002; 39: 190-194.
76. Megason SG, McMahon AP. A mitogen gradient of dorsal midline Wnts organizes growth in the CNS. Development. 2002; 129: 2087-2098.
77. Mendrzyk F, Radlwimmer B, Joos S, Kokocinski F, Benner A, Stange DE, Neben K, Fiegler H, Carter NP, Reifenberger G, Korshunov A, Lichter P. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol. 2005; 23: 8853-8862.
78. Michiels EM, Oussoren E, Van Groenigen M, Pauws E, Bossuyt PM, Voute PA, Baas F. Genes differentially expressed in medulloblastoma and fetal brain. Physiol Genomics. 1999; 1: 83-91.
79. Middleton FA, Strick PL. The cerebellum: an overview. Trends Neurosci. 1998; 21: 367-369.
80. Mulhern RK, Palmer SL, Merchant TE, Wallace D, Kocak M, Brouwers P, Krull K, Chintagumpala M, Stargatt R, Ashley DM, Tyc VL, Kun L, Boyett J, Gajjar A. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol. 2005; 23: 5511-5519.
81. Neben K, Korshunov A, Benner A, Wrobel G Hahn M, Kokocinski F, Golanov A, Joos S, Lichter P. Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res. 2004; 64: 3103-3111.
82. Nelson AL, Algon SA, Munasinghe J, Graves O, Goumnerova L, Burstein D, Pomeroy SL, Kim JY. Magnetic resonance imaging of patched heterozygous and xenografted mouse brain tumors. J Neurooncol. 2003; 62: 259-267.
83. Packer RJ. Childhood medulloblastoma: progress and future challenges. Brain Dev. 1999; 21: 75-81.
84. Packer RJ, Goldwein J, Nicholson HS, Vezina LG, Allen JC, Ris MD, Muraszko K, Rorke LB, Wara WM, Cohen BH, Boyett JM. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. J Clin Oncol. 1999; 17: 2127-2136.
85. Pan E, Pellarin M, Holmes E, Smirnov I, Misra A, Eberhart CG, Burger PC, Biegel JA, Feuerstein BG. Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res. 2005; 11: 4733-4740.
86. Park TS, Hoffman HJ, Hendrick EB, Humphreys RP, Becker LE. Medulloblastoma: clinical presentation and management. Experience at the hospital for sick children, toronto, 1950-1980. J Neurosurg. 1983; 58: 543-552.
87. Patapoutian A, Reichardt LF. Roles of Wnt proteins in neural development and maintenance. Curr Opin Neurobiol. 2000; 10: 392-399.
88. Pietsch T, Waha A, Koch A, Kraus J, Albrecht S, Tonn J, Sorensen N, Berthold F, Henk B, Schmandt N, Wolf HK, von Deimling A, Wainwright B, Chenevix-Trench G, Wiestler OD, Wicking C. Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res. 1997; 57: 2085-2088.
89. Pizem J, Cort A, Zadravec-Zaletel L, Popovic M. Survivin is a negative prognostic marker in medulloblastoma. Neuropathol Appl Neurobiol. 2005; 31: 422-428.
90. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, Kim JY, Goumnerova LC, Black PM, Lau C, Allen JC, Zagzag D, Olson JM, Curran T, Wetmore C, Biegel JA, Poggio T, Mukherjee S, Rifkin R, Califano A, Stolovitzky G, Louis DN, Mesirov JP, Lander ES, Golub TR. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002; 415: 436-442.
91. Raffel C, Jenkins RB, Frederick L, Hebrink D, Alderete B, Fults DW, James CD. Sporadic medulloblastomas contain PTCH mutations. Cancer Res. 1997; 1: 842-845.
92. Raimondi AJ, Tomita T. Hydrocephalus and infratentorial tumors. Incidence, clinical picture, and treatment. J Neurosurg. 1981; 55: 174-182.
93. Ray A, Ho M, Ma J, Parkes RK, Mainprize TG, Ueda S, McLaughlin J, Bouffet E, Rutka JT, Hawkins CE. A clinicobiological model predicting survival in medulloblastoma. Clin Cancer Res. 2004; 10: 7613-7620.
94. Reardon DA, Jenkins JJ, Sublett JE, Burger PC, Kun LK. Multiple genomic alterations including N-myc amplification in a primary large cell medulloblastoma. Pediatr Neurosurg. 2000; 32: 187-191.
95. Reardon DA, Michalkiewicz E, Boyett JM, Sublett JE, Entrekin RE, Ragsdale ST, Valentine MB, Behm FG, Li H, Heideman RL, Kun LE, Shapiro DN, Look AT. Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. Cancer Res. 1997; 57: 4042-4047.
96. Reifenberger J, Wolter M, Weber RG, Megahed M, Ruzicka T, Lichter P, Reifenberger G. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 1998; 58: 1798-1803.
97. Rickert CH, Paulus W. Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv Syst. 2001; 77: 502-511.
98. Rivera-Luna R, Lopez E, Rivera-Marquez H, Rivera-Ortegon F, Altamirano-Alvarez E, Mercado G, Covarrubias G, Rueda-Franco F, Marhx-Bracho A, Gutierrez P. Survival of children under 3 years old with medulloblastoma: a study from the Mexican Cooperative Group for Childhood Malignancies (AMOHP). Childs Nerv Syst. 2002; 18: 38-42.
99. Rood BR, Zhang H, Weitman DM, Cogen PH. Hypermethylation of HIC-1 and 17p allelic loss in medulloblastoma. Cancer Res. 2002; 62: 3794-3797.
100. Rossi MR, Conroy J, McQuaid D, Nowak NJ, Rutka JT, Cowell JK. Array CGH analysis of pediatric medulloblastomas. Genes Chromosomes Cancer. 2006; 45: 290-303.
101. Rutkowski S. Current treatment approaches to early childhood medulloblastoma. Expert Rev Neurother. 2006; 6: 1211-1221.
102. Schuller U, Rowitch DH. β-catenin function is required for cerebellar morphogenesis. Brain Res. 2006; 1140: 161-169.
103. Smyth I, Narang MA,, Evans T, Heimann C, Nakamura Y, Chenevix-Trench G, Pietsch T, Wicking C, Wainwright BJ. Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32. Hum Mol Genet. 1999; 8: 291-297.
104. Stearns D, Chaudhry A, Abel TW, Burger PC, Dang CV, Eberhart CG. c-myc overexpression causes anaplasia in medulloblastoma. Cancer Res. 2006; 66: 673-681.
105. Sung KW, Yoo KH, Cho EJ, Koo HH, Lim DH, Shin HJ, Ahn SD, Ra YS, Choi ES, Ghim TT. High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. Pediatr Blood Cancer. 2006; 25: 25.
106. Taipale J, Chen JK, Cooper MK, Wang B, Mann RK, Milenkovic L, Scott MP, Beachy PA. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature. 2000; 406: 1005-1009.
107. Taylor MD, Lui L, Raffel C, Hui CC, Mainprize TG, Zhang X, Agatep R, Chiappa S, Gao L, Lowrance A, Hao A, Goldstein AM, Stavrou T, Scherer SW, Dura WT, Wainwright B, Squire JA, Rutka JT, Hogg D. Mutations in SUFU predispose to medulloblastoma. Nat Genet. 2002; 31: 306-310.
108. ten Donkelaar HJ, Lammens M, Wesseling P, Thijssen HO, Renier WO. Development and developmental disorders of the human cerebellum. J Neurol. 2003; 250: 1025-1036.
109. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, Chintagumpala M, Adesina A, Ashley DM, Kellie SJ, Taylor MD, Curran T, Gajjar A, Gilbertson RJ. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006; 24: 1924-1931. Epub 2006 Mar 1927.
110. Tomlinson FH, Scheithauer BW, Meyer FB, Smithson WA, Shaw EG, Miller GM, Groover RV. Medulloblastoma: I. Clinical, diagnostic, and therapeutic overview. J Child Neurol. 1992; 7: 142-155.
111. Tong CY, Hui AB, Yin XL, Pang JC, Zhu XL, Poon WS, Ng HK. Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization. J Neurosurg. 2004; 100: 187-193.
112. Tong WM, Ohgaki H, Huang H, Granier C, Kleihues P, Wang ZQ. Null mutation of DNA strand break-binding molecule poly(ADP-ribose) polymerase causes medulloblastomas in p53(-/-) mice. Am J Pathol. 2003; 162: 343-352.
113. Triulzi F, Parazzini C, Righini A. MRI of fetal and neonatal cerebellar development. Semin Fetal Neonatal Med. 2005; 10: 411-420.
114. Verlooy J, Mosseri V, Bracard S, Tubiana AL, Kalifa C, Pichon F, Frappaz D, Chastagner P, Pagnier A, Bertozzi AI, Gentet JC, Sariban E, Rialland X, Edan C, Bours D, Zerah M, Le Gales C, Alapetite C, Doz F. Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study. Eur J Cancer. 2006; 42: 3004-3014. Epub 2006 Sep 3007.
115. Voogd J, Glickstein M. The anatomy of the cerebellum. Trends Neurosci. 1998; 21: 370-375.
116. Vorechovsky I, Tingby O, Hartman M, Stromberg B, Nister M, Collins VP, Toftgard R. Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumours. Oncogene. 1997; 15: 361-366.
117. Wang VY, Zoqhbi HY. Genetic regulation of cerebellar development. Nat Rev Neurosci. 2001; 2: 484-491.
118. Wechsler-Reya R, Scott MP. The developmental biology of brain tumors. Annu. Rev. Neurosci. 2001; 24: 385-428.
119. Wetmore C, Eberhart DE, Curran T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res. 2001; 61: 513-516.
120. Wingate RJ. The rhombic lip and early cerebellar development. Curr Opin Neurobiol. 2001; 11: 82-88.
121. Yamada K, Watanabe M. Cytodifferentiation of Bergmann glia and its relationship with Purkinje cells. Anat Sci Int. 2002; 77: 94-108.
122. Yokota N, Nishizawa S, Ohta S, Date H, Sugimura H, Namba H, Maekawa M. Role of Wnt pathway in medulloblastoma oncogenesis. Int J Cancer. 2002; 101: 198-201.
123. Zechner D, Fujita Y, Hulsken J, Muller T, Walther I, Taketo MM, Crenshaw EB, 3rd, Birchmeier W, Birchmeier C. β-Catenin signals regulate cell growth and the balance between progenitor cell expansion and differentiation in the nervous system. Dev Biol. 2003; 258: 406-418.
124. Zurawel RH, Allen C, Chiappa S, Cato W, Biegel J, Cogen P, de Sauvage F, Raffel C. Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes Chromosom Cancer. 2000; 27: 44-51.